ASH 2023 | Advances in LR-MDS and HR-MDS in 2023 and beyond
Amer Zeidan, MBBS, Yale Cancer Center, New Haven, CT, highlights that 2023 has been an important year in the management of low-risk myelodysplastic syndromes (LR-MDS). Recent advances include the first approval of luspatercept in the front-line setting in patients with LR-MDS and data from the Phase III IMerge (NCT02598661) study for imetelstat – a first-in-class telomerase inhibitor – which showed a positive outcome. Dr Zeidan notes that the next steps will be to look at combination therapies and use them in the early phases of treatment, potentially pre-transfusion dependence. The updates in high-risk MDS (HR-MDS) have not been as noteworthy, with a negative outcome for magrolimab. However, Dr Zeidan notes that there are ongoing trials in HR-MDS that will hopefully be more positive in 2024. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Schrödinger, Notable, Chiesi, Mendus, Otsuka, Foran, Syros, ALX Oncology, Kura, Seattle Genetics, Servier, Boehringer-Ingelheim, Jazz, Orum, Geron, Syndax, Gilead, Zentalis, BeyondSpring, Incyte, Pfizer, Celgene/BMS, Janssen, Amgen, Agios, Daiichi Sankyo, Tyme, Taiho, AbbVie, Ionis, Takeda, Genentech, Epizyme, Lox Oncology, Novartis, Astellas, BioCryst, Regeneron
Honoraria: Schrödinger, Notable, Chiesi, Mendus, Otsuka, Foran, Syros, ALX Oncology, Kura, Seattle Genetics, Servier, Boehringer-Ingelheim, Jazz, Orum, Geron, Syndax, Gilead, Zentalis, BeyondSpring, Incyte, Pfizer, Celgene/BMS, Janssen, Amgen, Agios, Daiichi Sankyo, Tyme, Taiho, AbbVie, Ionis, Takeda, Genentech, Epizyme, Lox Oncology, Novartis, Astellas, BioCryst, Regeneron
Research Funding: Foran, Shattuck Labs, Astex
